DOE A to Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #


AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals’ funding priority is programs which improve health, and particularly patient health, such as programs focused directly on patients or their caregivers (e.g., patient education materials, disease-awareness campaigns or temporary living quarters for patients and their families); or efforts intended to improve the provision of health care (e.g., increased access for underserved or disadvantaged populations). In keeping with the corporate mission to improve patient health in the therapeutic areas of our business, priority will be given to requests that focus on diseases or conditions in our medical areas of research, which are cardiovascular, oncology, gastrointestinal, central nervous system and respiratory disease. In addition, we will also consider programs that work to ameliorate important societal problems and/or improve quality of life (e.g., programs enhancing education, or the lives of seniors, minorities or the aging), and activities that enhance the public good in general, such as support for the arts and culture.

Eligibility:Tax-exempt 501(c)(3) non-profit organization. The charity’s mission or program must be designed to further the common good, and most often, have a strong connection to health care and have a lasting impact. Charitable contributions may be unrestricted (for general operating expenses) or may be designated to support a specific project or program.


Contact:Corporate Community Alliances, 1800 Concord Pike, Wilmington, DE 19850-5437


Federal: No